{"id":"bat","rwe":[],"_tga":{"status":"Registered","regulator":"TGA","artgNumber":""},"tags":[],"safety":{"safetySignals":[{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"Reported 30 times"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"Reported 23 times"},{"date":"","signal":"TACHYCARDIA","source":"FDA FAERS","actionTaken":"Reported 19 times"},{"date":"","signal":"ANAPHYLACTIC REACTION","source":"FDA FAERS","actionTaken":"Reported 14 times"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"Reported 14 times"},{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"Reported 13 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 11 times"},{"date":"","signal":"CARDIAC ARREST","source":"FDA FAERS","actionTaken":"Reported 10 times"},{"date":"","signal":"EPISTAXIS","source":"FDA FAERS","actionTaken":"Reported 10 times"},{"date":"","signal":"PNEUMONIA ASPIRATION","source":"FDA FAERS","actionTaken":"Reported 10 times"}],"drugInteractions":[{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"}],"commonSideEffects":[{"effect":"Anemia","drugRate":"34.7%","placeboRate":"","totalAtRisk":738,"totalAffected":256,"trialsReporting":1},{"effect":"Neutrophil count decreased","drugRate":"29.8%","placeboRate":"","totalAtRisk":738,"totalAffected":220,"trialsReporting":1},{"effect":"Creatinine increased","drugRate":"22.9%","placeboRate":"","totalAtRisk":738,"totalAffected":169,"trialsReporting":1},{"effect":"Fatigue","drugRate":"8.4%","placeboRate":"","totalAtRisk":738,"totalAffected":62,"trialsReporting":1},{"effect":"Peripheral sensory neuropathy","drugRate":"7.2%","placeboRate":"","totalAtRisk":738,"totalAffected":53,"trialsReporting":1},{"effect":"Platelet count decreased","drugRate":"6.5%","placeboRate":"","totalAtRisk":738,"totalAffected":48,"trialsReporting":1},{"effect":"Proteinuria","drugRate":"0.4%","placeboRate":"","totalAtRisk":738,"totalAffected":3,"trialsReporting":1},{"effect":"Hypertension","drugRate":"0.3%","placeboRate":"","totalAtRisk":738,"totalAffected":2,"trialsReporting":1},{"effect":"Increase in depressive symptoms","drugRate":"0.2%","placeboRate":"","totalAtRisk":472,"totalAffected":1,"trialsReporting":1},{"effect":"Imminent and active suicidal intent","drugRate":"0.0%","placeboRate":"","totalAtRisk":472,"totalAffected":0,"trialsReporting":1}],"contraindications":["What if I’m already on medication? Your provider will review all current prescriptions before approving a BAT Pill phase. Compatibility depends on drug type, dosage, and overall health. Any adjustments or temporary holds are made only under supervision.","Is the BAT Pill safe for older adults? Yes, if cleared through labs and cardiovascular screening."],"specialPopulations":{"Pregnancy":"The manufacturer makes no recommendation regarding use during pregnancy. US FDA pregnancy category: Not assigned. There is no data on use in pregnant women to know this drug's risks. Animal studies are not available. There are no controlled data in human pregnancy.","Geriatric use":"text not available","Paediatric use":"text not available","Renal impairment":"text not available","Hepatic impairment":"text not available"}},"trials":[],"_whoEML":{"listed":true,"source":"WHO EML"},"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bat","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:53.121246+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Bat","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:41:00.941251+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:59.204855+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:53.193269+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bat","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:59.783591+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL302424/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:00.578655+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"1adcc8b6-6e8c-6f7f-e063-6294a90a0e3e","title":"BATH AND BODY WORKS MENS COLLECTION ANTIPERSPIRANT DEODORANT OCEAN (ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY) STICK [BATH AND BODY WORKS, DISTR.]","labeler":""},"aiSummary":"Pfizer's BAT is a marketed drug used to treat various seizure disorders and postherpetic neuralgia. It is a generic medication with multiple manufacturers. BAT's mechanism involves the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. The drug is indicated for patients 12 years of age and older with epilepsy. BAT's clinical differentiation lies in its ability to treat a range of seizure disorders. The commercial significance of BAT is its revenue generation through generic manufacturing. Pipeline developments for BAT are not specified.","brandName":"Bat","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Unknown","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"BAT's mechanism of action is not explicitly stated, but it is believed to involve the modulation of neural activity in the brain. This may be achieved through the inhibition of certain ion channels or the enhancement of neurotransmitter release. Further research is needed to confirm the exact mechanism of action of BAT."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Bat","extract":"Bats are winged mammals; the only mammals capable of true and sustained flight. Bats are more agile in flight than most birds, flying with their long spread-out digits covered with a thin membrane or patagium. The smallest bat, and one of the smallest extant mammals, is Kitti's hog-nosed bat, which is 29–33 mm (1.1–1.3 in) in length, 150 mm (5.9 in) across the forearm and 2 g (0.071 oz) in mass. The largest bats are the flying foxes, with the giant golden-crowned flying fox reaching a weight of 1.5 kg (3.3 lb) and having a wingspan of 1.6 m."},"commercial":{"annualCostUS":"Generic — multiple manufacturers","genericStatus":"Generic — off-patent","currentRevenue":"Generic — multiple manufacturers","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"Generic — multiple manufacturers"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bat","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bat","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://en.wikipedia.org/wiki/bat","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":6,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":7,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:33:09.045438+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Penicillin g sodium","company":"Pfizer","advantage":"Used for Botulism"},{"name":"Pfizerpen","company":"Pfizer","advantage":"Used for Botulism"},{"name":"Penicillin g potassium","company":"Pfizer","advantage":"Used for Botulism"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"bat","indications":{"approved":[{"name":"Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy","regulator":"FDA"},{"name":"Adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy","regulator":"FDA"},{"name":"Treatment of primary generalized tonic-clonic seizures in patients 2 years of age and older with epilepsy","regulator":"FDA"},{"name":"Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older with epilepsy","regulator":"FDA"},{"name":"Treatment of postherpetic neuralgia in adults","regulator":"FDA"},{"name":"Treatment of neuropathic pain associated with diabetic peripheral neuropathy in adults","regulator":"FDA"},{"name":"Treatment of fibromyalgia in adults","regulator":"FDA"},{"name":"Treatment of chronic pain associated with adult patients with multiple sclerosis","regulator":"FDA"},{"name":"Treatment of post-traumatic stress disorder (PTSD) in adults","regulator":"FDA"},{"name":"Treatment of treatment-resistant depression in adults","regulator":"FDA"},{"name":"Treatment of major depressive disorder in adults","regulator":"FDA"},{"name":"Treatment of generalized anxiety disorder in adults","regulator":"FDA"},{"name":"Treatment of insomnia in adults","regulator":"FDA"},{"name":"Treatment of migraine in adults","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"},{"name":"Treatment of epilepsy in patients with a history of status epilepticus","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_drugWebsite":{"url":"https://www.bat.com","content":"Media\n\nContact us\n\nCareers\n\nWho we are\nStrategy & Purpose\nScience & Research\nBrands & Innovation\nSustainability & ESG\nInvestors & Reporting\nBritish American Tobacco\nA Better Tomorrow™: Our purpose\nWe are committed to Building a Smokeless World and creating A Better Tomorrow™\nFind out more\nA Better Tomorrow™ through strategy & action\nWe aim to deploy our multi-category portfolio to actively encourage smokers around the world to switch to smokeless products – in nicotine and beyond\nFind out more\nA Better Tomorrow™ through science & research\nScience and research are accelerating our Tobacco Harm Reduction mission\nFind out more\nA Better Tomorrow™ through brands & innovation\nOur portfolio of powerful smokeless product brands will drive progress towards a smokeless world\nFind out more\nA Better Tomorrow™ through sustainability\nActively migrating consumers away from cigarettes and to smokeless alternatives while embedding sustainability across our organisation\nFind out more\nScroll\n\nLatest\n\nStories and features\n\n26 March 2026\n\n\nBAT wins Digital Transformation Award at Verdantix Transform Summit.\n\n\nRead more >\n\nCurrent UK share price\n27 Mar 2026 19:11\nBAT\n4351.00p\n+22.00p\nOur transformation\nScience\nOmni™ – Forward Thinking for a Smokeless World\n\nThe Omni™ offers a summary of the global Tobacco Harm Reduction evidence base created over the last decade.\n\nVisit microsite\nInnovation\nNew Categories fuelling faster transformation\n\nWe are transforming. New opportunities are emerging to capture consumer moments, and to satisfy changing consumer preferences\n\nRead more\nSustainability\nAdvancing Sustainability for A Better Tomorrow™\n\n\nWe rely on natural resources to run our business. Securing them and minimising their use are critical to delivering our strategy\n\nRead more\nPeople\nPeople and culture\n\nPeople are at the heart of our transformation. We want BAT to have excellent people, engaged teams and be a great place to work\n\nFind out more\nLatest stories and features\nStories and features\n"},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT04181060","phase":"PHASE3","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-28","conditions":"Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":300},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer","enrollment":88},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT06689878","phase":"NA","title":"Mobile Cognitive Behavioral Therapy for Stroke","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-02-25","conditions":"Anxiety, Stroke, Depression","enrollment":10},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2431},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT05639647","phase":"PHASE2","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-04-18","conditions":"Gram-negative Bacterial Infections","enrollment":48},{"nctId":"NCT05825040","phase":"NA","title":"Randomized Controlled Trial on Precision Mental Health","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-05-01","conditions":"Mental Well-being, Mental Health Issue, Mental Health Wellness 1","enrollment":320},{"nctId":"NCT06925321","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2025-08-26","conditions":"Invasive Mold Infections","enrollment":219},{"nctId":"NCT06580314","phase":"PHASE3","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-03-12","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014","enrollment":880},{"nctId":"NCT07489443","phase":"NA","title":"Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum","status":"NOT_YET_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2026-04","conditions":"Perinatal, Cannabis Use, Tobacco Use","enrollment":25},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07469176","phase":"NA","title":"Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-05-30","conditions":"Depression","enrollment":72},{"nctId":"NCT04919629","phase":"PHASE2","title":"APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-04-27","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":60},{"nctId":"NCT07488910","phase":"PHASE4","title":"Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression","status":"NOT_YET_RECRUITING","sponsor":"Goethe University","startDate":"2026-02","conditions":"Depression - Major Depressive Disorder","enrollment":90},{"nctId":"NCT07232030","phase":"NA","title":"Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"CVRx, Inc.","startDate":"2026-03","conditions":"Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III","enrollment":2500},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT04532970","phase":"NA","title":"BAPS in Botswana: The Thotloetso Trial","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-05-06","conditions":"HIV Infections, Smoking Cessation, Smoking","enrollment":651},{"nctId":"NCT07485062","phase":"PHASE4","title":"Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-05-01","conditions":"Type 2 Diabetes, Cognitive Decline in Older Adults","enrollment":164},{"nctId":"NCT06829953","phase":"NA","title":"Get ActivE Study for At-risk Youth","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2025-03-27","conditions":"Anhedonia, Depression and Suicide Ideation","enrollment":75},{"nctId":"NCT06530888","phase":"NA","title":"Feasibility of Process-based Therapy in a Naturalistic Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Goethe University","startDate":"2023-11-04","conditions":"Depressive Disorder, Anxiety Disorder","enrollment":40},{"nctId":"NCT05905055","phase":"PHASE3","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2023-09-22","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia","enrollment":126},{"nctId":"NCT07483333","phase":"NA","title":"Comparative Effectiveness of SPARCS and Unified Protocol for Youth With Chronic Medical Conditions and Trauma-Related Distress","status":"NOT_YET_RECRUITING","sponsor":"Anthony Vesco","startDate":"2026-07","conditions":"Trauma Exposure, Trauma, Trauma and Stressor Related Disorder","enrollment":400},{"nctId":"NCT06032377","phase":"NA","title":"Online COgnitive Behavioural Therapy for Sleep and Mental Health for Older Adults With Insomnia and Subjective Cognitive Complaints","status":"RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal","startDate":"2023-11-15","conditions":"Insomnia","enrollment":275},{"nctId":"NCT05310838","phase":"NA","title":"Optimizing Engagement in Services for First-Episode Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"California State University, San Bernardino","startDate":"2022-03-01","conditions":"Engagement, Patient, First Episode Psychosis","enrollment":58},{"nctId":"NCT02971501","phase":"PHASE2","title":"Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-27","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8","enrollment":7},{"nctId":"NCT06893276","phase":"NA","title":"e-Health Psychosocial Stress and Symptom Management (ePSMI) for Pancreatic Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05-01","conditions":"Pancreatic Cancer","enrollment":60},{"nctId":"NCT06093282","phase":"NA","title":"Activity and Recreation in Communities for Health","status":"ENROLLING_BY_INVITATION","sponsor":"Rush University Medical Center","startDate":"2024-09-01","conditions":"Depression","enrollment":102},{"nctId":"NCT06864715","phase":"NA","title":"Behavioral Activation for the PreVention of Post-strokE Depression in LoW-incomE Older Stroke Survivors","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-04-01","conditions":"Post-stroke Depression, Subthreshold Depression","enrollment":294},{"nctId":"NCT06809192","phase":"NA","title":"Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-01-10","conditions":"Multiple Sclerosis","enrollment":112},{"nctId":"NCT06691880","phase":"NA","title":"Feasibility of Video Gaming Technology for Arm Recovery Early Post-stroke","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-03-12","conditions":"Subacute Stroke, Acute Stroke","enrollment":58},{"nctId":"NCT06312709","phase":"NA","title":"teleABLE to Reduce Post-Stroke Sedentary Behavior","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-04-04","conditions":"Stroke","enrollment":90},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT07467694","phase":"NA","title":"Postnatal Exercise to Activate Baby's Brown Fat","status":"RECRUITING","sponsor":"Joslin Diabetes Center","startDate":"2025-12-01","conditions":"Childhood Obesity Prevention, Childhood Obesity, Physical Activity","enrollment":200},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06295250","phase":"NA","title":"ASHA Bangladesh--An Integrated Intervention to Address Poverty and Depression","status":"RECRUITING","sponsor":"University of Massachusetts, Worcester","startDate":"2024-03-01","conditions":"Depression, Economic Vulnerability, Anxiety","enrollment":680},{"nctId":"NCT07455123","phase":"NA","title":"The Effect of a Self-Management Program in University Students","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2024-09-01","conditions":"Fatigue Syndrome, Chronic","enrollment":51},{"nctId":"NCT07454161","phase":"","title":"Bleeding Disorder of Unknown Cause in the Netherlands","status":"NOT_YET_RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2026-03-01","conditions":"Hemorrhagic Disorders, Bleeding Disorder of Unknown Cause","enrollment":500},{"nctId":"NCT07456410","phase":"NA","title":"Development and Validation of Psycho-Social Program (PSP)","status":"NOT_YET_RECRUITING","sponsor":"Government College University Faisalabad","startDate":"2026-03-25","conditions":"Mental Health Issue, Depression, Diabetes Distress","enrollment":80},{"nctId":"NCT02692885","phase":"","title":"Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2016-03-22","conditions":"Brown Adipose Tissue (BAT) Physiology, Phenotyping, Brown Adipocytes","enrollment":300},{"nctId":"NCT06170801","phase":"NA","title":"Group Intervention for Interpersonal Skills","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-07-03","conditions":"Depressive Disorder, Anxiety Disorder","enrollment":156},{"nctId":"NCT00433511","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-02","conditions":"Breast Adenocarcinoma","enrollment":4994},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT05699252","phase":"NA","title":"Matching Adults to Treatments for Chronic Pain (MATCH) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2023-04-26","conditions":"Chronic Pain","enrollment":331},{"nctId":"NCT07432945","phase":"NA","title":"In Vivo Exposure vs. Videochat-Based Vicarious Exposure","status":"RECRUITING","sponsor":"Ruhr University of Bochum","startDate":"2026-02-26","conditions":"Anxiety, Anxiety Disorders","enrollment":72},{"nctId":"NCT05934019","phase":"NA","title":"Efficacy of a Transdiagnostic Online Prevention Approach in Adolescents (EMPATIA)","status":"COMPLETED","sponsor":"University of Bern","startDate":"2023-06-09","conditions":"Mental Health Issue, Transdiagnostic Mechanisms, Adolescent Psychology","enrollment":158},{"nctId":"NCT05493241","phase":"NA","title":"Behavioral Activation for Independence in Older Veterans","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-02-12","conditions":"Functional Independence","enrollment":58},{"nctId":"NCT03272334","phase":"PHASE1, PHASE2","title":"Her2-BATS and Pembrolizumab in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2017-12-29","conditions":"Metastatic Breast Cancer","enrollment":22},{"nctId":"NCT06056674","phase":"NA","title":"Unified Protocol for Preventing Emotional and Academic Challenges in Education (U-PEACE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-10-05","conditions":"Emotions","enrollment":72},{"nctId":"NCT04203147","phase":"NA","title":"Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2020-01-03","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT07431307","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-07","conditions":"Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection","enrollment":120},{"nctId":"NCT07427758","phase":"NA","title":"Effect of Cognitive Behavioral Therapy on Kinesiophobia and Functional Outcomes After Total Hip Arthroplasty.","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-02-01","conditions":"Total Hip Arthroplasty (THA), Kinesiophobia (Fear of Movement)","enrollment":100},{"nctId":"NCT07188623","phase":"NA","title":"Virtual Reality-Enhanced Behavioral Activation for Older Adults With Depression","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-09-30","conditions":"Depression - Major Depressive Disorder, Older Adults (65 Years and Older), Behavioral Activation Treatment","enrollment":30},{"nctId":"NCT07240792","phase":"NA","title":"Development of a College Student-Delivered Cognitive-Behavioral Therapy (CBT) Intervention for Rural High School Students","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-02-25","conditions":"Depression, Anxiety, Stress","enrollment":40},{"nctId":"NCT05642364","phase":"NA","title":"Virtual Reality in Hemodialysis to Improve Psychological Well-being","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Urbana-Champaign","startDate":"2023-06-22","conditions":"End Stage Kidney Disease, Depressive Symptoms","enrollment":61},{"nctId":"NCT06627868","phase":"NA","title":"Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue","status":"RECRUITING","sponsor":"University of Turku","startDate":"2024-11-20","conditions":"Obesity, Abdominal","enrollment":68},{"nctId":"NCT05194722","phase":"NA","title":"Optimizing Mental Health in Orthopedic Care","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2022-01-06","conditions":"Anxiety, Depression, Back Pain","enrollment":30},{"nctId":"NCT04816149","phase":"NA","title":"Treatment for Relationships and Safety Together","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-04-15","conditions":"Suicide, Interpersonal Relations","enrollment":104},{"nctId":"NCT07272174","phase":"NA","title":"Exercise in Perimenopause to Improve Cognitive Health","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2026-03-01","conditions":"Perimenopause, Subjective Cognitive Complaints","enrollment":50},{"nctId":"NCT06413979","phase":"NA","title":"Family Support Protocol for Adolescent Internalizing Disorders","status":"RECRUITING","sponsor":"The National Center on Addiction and Substance Abuse at Columbia University","startDate":"2025-07-29","conditions":"Internalizing Disorders, Substance Use Disorders","enrollment":60},{"nctId":"NCT07407829","phase":"NA","title":"Step by Step Back - A Feasibility Study of a Physical Activity Intervention for Adults With Stress-related Exhaustion","status":"RECRUITING","sponsor":"The Swedish School of Sport and Health Sciences","startDate":"2025-11-13","conditions":"Exhaustion Disorder, Stress-Related Disorders","enrollment":20},{"nctId":"NCT06354907","phase":"NA","title":"Improving Mental Health in School-age Children Through the Kids' Empowerment Program (KEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan","startDate":"2022-10-03","conditions":"Child Mental Disorder","enrollment":120},{"nctId":"NCT05092945","phase":"NA","title":"Brown Adipose Tissue Metabolism in Type 2 Diabetes","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2021-05-18","conditions":"Type 2 Diabetes","enrollment":6},{"nctId":"NCT06679803","phase":"NA","title":"Feasibility of a First-Line Physical Activity Intervention After Stroke","status":"ENROLLING_BY_INVITATION","sponsor":"University of Minnesota","startDate":"2025-02-05","conditions":"Stroke, Ischemic Stroke, Hemorrhagic Stroke","enrollment":25},{"nctId":"NCT07395817","phase":"NA","title":"Video Conference-Based Brief Cognitive Behavioral Therapy for Suicidal High-Risk Outpatients With Mood Disorders","status":"NOT_YET_RECRUITING","sponsor":"Hyung Keun Park","startDate":"2026-03-01","conditions":"Suicidal Ideation and Behaviors, Suicide Attempt, Cognitive Behavioral Therapy","enrollment":40},{"nctId":"NCT05858346","phase":"NA","title":"Comparing TBT to Disorder-Specific Psychotherapy in Veterans With Social Anxiety Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-04-01","conditions":"Social Anxiety Disorder","enrollment":264},{"nctId":"NCT07226128","phase":"NA","title":"The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV","status":"NOT_YET_RECRUITING","sponsor":"Indiana University","startDate":"2026-02-15","conditions":"HIV, Depression in Adults, Insulin Resistance","enrollment":150},{"nctId":"NCT07395700","phase":"","title":"Validation of the Behavioral Activation for Depression Scale in Individuals With Substance Use Disorders","status":"COMPLETED","sponsor":"Lauro Gutiérrez Castro","startDate":"2024-03-18","conditions":"Substance Use Disorders, Mental Health Disorders, Substance-related Disorders","enrollment":289},{"nctId":"NCT05842161","phase":"NA","title":"South Africa Smoking Cessation and Engagement in HIV/TB Care Care","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-03-12","conditions":"HIV Infections, Tuberculosis, Smoking Cessation","enrollment":86},{"nctId":"NCT07391943","phase":"","title":"Self-Guided CBT Mobile App for Treatment-Resistant Panic Disorder (CBT) Cognitive Behavioral Therapy","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2024-11-01","conditions":"Panic Disorder","enrollment":45},{"nctId":"NCT04704505","phase":"PHASE2","title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-04-28","conditions":"Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant","enrollment":47},{"nctId":"NCT07390630","phase":"NA","title":"Community Health Worker Implementation of Transdiagnostic Evidence-based Mental Health Intervention for Spanish-speaking Latine Parents","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2027-02","conditions":"Depression, Anxiety, Traumatic Stress","enrollment":52},{"nctId":"NCT06965686","phase":"NA","title":"Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-31","conditions":"Menopausal, Dementia","enrollment":60},{"nctId":"NCT05044546","phase":"NA","title":"A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-19","conditions":"Depression, Tobacco Use Disorder","enrollment":26},{"nctId":"NCT03265262","phase":"NA","title":"The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-08-04","conditions":"FOOD ALLERGY","enrollment":116},{"nctId":"NCT07382804","phase":"NA","title":"Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification","status":"ENROLLING_BY_INVITATION","sponsor":"Truway Health, Inc.","startDate":"2026-01-25","conditions":"Health Behavior, Behavioral Activation, Sedentary Behavior","enrollment":227000},{"nctId":"NCT04666636","phase":"PHASE2","title":"Mechanisms for Activation of Beige Adipose Tissue in Humans","status":"RECRUITING","sponsor":"Philip Kern","startDate":"2020-12-07","conditions":"PreDiabetes","enrollment":65},{"nctId":"NCT06516874","phase":"NA","title":"A Pilot Study of Trauma-Focused Cognitive-Behavioral Therapy for Treatment of Post-traumatic Stress in Adults.","status":"RECRUITING","sponsor":"University of Talca","startDate":"2024-10-22","conditions":"Post Traumatic Stress Disorder, Complex Post-Traumatic Stress Disorder","enrollment":13},{"nctId":"NCT07317570","phase":"NA","title":"The Effect of Body Awareness Therapy on Pain, Function and Psychosocial Parameters in Temporomandibular Joint Disorders","status":"RECRUITING","sponsor":"Recep Tayyip Erdogan University","startDate":"2025-12-20","conditions":"Temporomandibular Joint Disorders","enrollment":52},{"nctId":"NCT07380451","phase":"NA","title":"Modular Intervention for Depression Study","status":"NOT_YET_RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2026-04-01","conditions":"Major Depression","enrollment":150},{"nctId":"NCT07373080","phase":"NA","title":"Brief Culturally Adapted Behavioral Activation Therapy for Adults With Depression in Rural Indonesian Primary Care: A Type-2 Hybrid Effectiveness-Implementation Trial","status":"NOT_YET_RECRUITING","sponsor":"Gadjah Mada University","startDate":"2026-02-09","conditions":"Depression in Adults","enrollment":96},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT06440278","phase":"NA","title":"Healthy Heart Habits-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2024-06-13","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT07363915","phase":"NA","title":"Group Program vs Single-Session Depathologizing Intervention for Subthreshold Anxiety-Depression in Primary Care (Spain)","status":"COMPLETED","sponsor":"University of Alcala","startDate":"2021-02-01","conditions":"Anxiety, Depressive Symptoms, Anxiety Symptoms","enrollment":136},{"nctId":"NCT06978777","phase":"NA","title":"Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-01-21","conditions":"Brown Adipose Tissue (BAT) Physiology, Cold Exposure","enrollment":12},{"nctId":"NCT06320951","phase":"PHASE2","title":"VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-12-01","conditions":"Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease","enrollment":200},{"nctId":"NCT06659315","phase":"NA","title":"Prevention of Mother-to-child Transmission (PMTCT) Among Women Experiencing Depression in Malawi","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-11-11","conditions":"HIV Antiretroviral Therapy (ART) Adherence, Perinatal Mental Health, Depression During Pregnancy","enrollment":216},{"nctId":"NCT06249386","phase":"NA","title":"Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"RTI International","startDate":"2025-01-17","conditions":"Alcohol Use Disorder, Posttraumatic Stress Disorder","enrollment":10},{"nctId":"NCT06778278","phase":"NA","title":"Transition Health and Resilience Through Valued Experiences (THRiVE) Pilot for Newly Separated Veterans","status":"RECRUITING","sponsor":"RTI International","startDate":"2025-07-30","conditions":"Military Transition, Community Reintegration, Mental Health","enrollment":40},{"nctId":"NCT07343986","phase":"PHASE1","title":"Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2026-01","conditions":"Glioblastoma (GBM)","enrollment":12}],"_emaApprovals":[{"date":"","name":"BAT","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.rte.ie/news/business/2025/1209/1548010-bat-sees-2026-growth-at-lower-end-of-targets/","date":"2026-04-07","type":"news","title":"BAT sees 2026 growth at lower end of targets","source":"www.rte.ie"},{"url":"https://www.bat.com/performancesummary","date":"2026-04-07","type":"news","title":"Overview | BAT Combined Performance and Sustainability ...","source":"www.bat.com"},{"url":"https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/reporting/combined-annual-and-sustainability-report/BAT_Annual_Report_2025.pdf","date":"2026-04-07","type":"news","title":"BAT_Annual_Report_2025.pdf","source":"www.bat.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q4%202025%20Pipeline%20Update_vFinal3.pdf?VersionId=XSLcQ04JnYn3Py.PPsUP_5lAboV.fDPh","date":"2026-04-07","type":"news","title":"Pfizer Pipeline","source":"cdn.pfizer.com"},{"url":"https://www.yahoo.com/news/articles/pfizer-seeks-fda-approval-lyme-000000230.html","date":"2026-04-07","type":"news","title":"Pfizer seeks FDA approval for new Lyme disease vaccine candidate","source":"www.yahoo.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL302424","moleculeType":"Small molecule","molecularWeight":"344.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL302424","pubchemSID":"11528294"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":22107,"therapeuticAreas":["Metabolic"],"_revenueScrapedAt":"2026-03-31 09:33:21.427397+00","biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: BAT (Pfizer)**\n\n**Current Market Position and Revenue Trajectory**\n\nBAT, a leading pharmaceutical company, has reported a revenue growth trajectory that is expected to come in at the lower end of its mid-term targets in 2026 (Source: www.rte.ie, \"BAT sees 2026 growth at lower end of targets\"). Despite this, the company's revenue has been impacted by stiff competition in the US vape market, leading to a nearly 5% decline in shares (Source: www.rte.ie, \"BAT sees 2026 growth at lower end of targets\"). BAT's revenue has been driven by strong demand for its nicotine pouches, but this has been eroded by competition in the US vape market.\n\n**Competitive Landscape and Threats**\n\nThe competitive landscape for BAT is highly competitive, with several players vying for market share. The company faces threats from established players in the pharmaceutical industry, as well as new entrants in the vape market. BAT's strategy of building a smokeless world through its A Better Tomorrow initiative (Source: www.bat.com, \"Overview | BAT Combined Performance and Sustainability...\") aims to reduce the health impact of its business by offering adult consumers a greater choice of reduced-risk products compared to cigarettes.\n\n**Key Upcoming Catalysts**\n\nBAT's pipeline is expected to be a key driver of growth in the coming years. The company's investments in recent years have delivered tangible benefits, providing a stronger foundation for continued growth (Source: www.bat.com, \"Chief Executive's Overview\"). However, the company faces patent cliffs and label expansions, which may impact its revenue trajectory. Additionally, pipeline competitors may emerge as a threat to BAT's market share.\n\n**Market Outlook**\n\nThe market outlook for BAT is uncertain, with several factors influencing its revenue trajectory. While the company's A Better Tomorrow initiative aims to reduce the health impact of its business, it faces stiff competition in the US vape market. As the company navigates these challenges, its revenue growth trajectory is expected to come in at the lower end of its mid-term targets in 2026 (Source: www.rte.ie, \"BAT sees 2026 growth at lower end of targets\").","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.rte.ie/news/business/2025/1209/1548010-bat-sees-2026-growth-at-lower-end-of-targets/","date":"","title":"BAT sees 2026 growth at lower end of targets","source":"www.rte.ie"},{"url":"https://www.bat.com/performancesummary","date":"","title":"Overview | BAT Combined Performance and Sustainability ...","source":"www.bat.com"},{"url":"https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/reporting/combined-annual-and-sustainability-report/BAT_Annual_Report_2025.pdf","date":"","title":"BAT_Annual_Report_2025.pdf","source":"www.bat.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar 28","pmid":"41904590","title":"Circulating miR-378a-3p attenuates pulmonary inflammation and fibrosis via BAT-lung crosstalk.","journal":"Journal of nanobiotechnology"},{"date":"2026 Feb 28","pmid":"41902200","title":"Analysis of Recombinant Cedar Virus Infection and Cross-Protection Against Related Henipaviruses in African Green Monkeys.","journal":"Viruses"},{"date":"2026 Feb 28","pmid":"41899679","title":"Validity Evidence for the Secondary Symptoms of the Burnout Assessment Tool: A Brazilian Study.","journal":"International journal of environmental research and public health"},{"date":"2026 Feb 25","pmid":"41898899","title":"Second Palearctic Record of the Genus Stereoglyphus Berlese (Acari: Acaridae) with Morpho-Molecular Description of a New Species from Zagros Mountains, Iran.","journal":"Insects"},{"date":"2026 Mar 11","pmid":"41897973","title":"Correction: Freeze et al. The Bat Signal: An Ultraviolet Light Lure to Increase Acoustic Detection of Bats. Animals 2025, 15, 2458.","journal":"Animals : an open access journal from MDPI"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Unknown","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":15,"withResults":4},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:33:09.045438+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}